NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
NeOnc is also evaluating NEO100 in patients with IDH mutations as part of its approach to selecting patients by tumor characteristics.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NTHI) outlined plans for an international brain cancer trial targeting approximately 500 patients across three countries. The proposed study envisions around 30 hospitals; these targets are not completed enrollment.
The investigational NEO100 program uses administration through the nose, designed to bypass the blood-brain barrier that can prevent therapies from reaching brain tumors. A December 2025 clinical update reported significant radiographic remission in six of 25 patients across combined clinical and compassionate-use experience. These preliminary observations came from a small, nonrandomized population and do not establish effectiveness or predict individual outcomes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed trial targets approximately 500 patients across around 30 hospitals in three countries.
- Minor pointSignificant radiographic remission occurred in six of 25 patients across combined clinical and compassionate-use experience.
Negative
- Minor pointRemission observations are preliminary and nonrandomized, from a small population, and do not establish treatment effectiveness.
Details
Market move: NTHI +5.66% vs previous close. international trial expansion
On Oct 26, the day this news came out, the latest delayed price for NTHI is 5.66% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $3.46. Relative volume is very high at 4.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Planned trial enrollment
- Approximately 500 patients
- Proposed international trial; planned participation, not completed enrollment
- Planned hospital sites
- 30 hospitals
- Proposed international trial
- Planned countries
- 3 countries
- Proposed international trial
- Reported remission
- 24% remission (6 of 25 patients)
- December 2025 update; combined clinical and compassionate-use experience; preliminary, nonrandomized observations
Key Terms
blood-brain barrier medical
intranasal administration medical
precision medicine medical
nonrandomized technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Health Uncensored with Dr. Drew spotlights ambitious international trial plans, a novel delivery approach and the patient experiences driving NeOnc’s research
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial targeting approximately 500 patients across 30 hospitals in three countries during a discussion on Health Uncensored with Dr. Drew, on Fox Business Network.
The proposed expansion brings fresh attention to NeOnc’s effort to address one of brain cancer treatment’s toughest challenges: delivering potential therapies into the brain. The discussion connected the scale of the company’s ambitions with its investigational treatment strategy, early clinical observations and the patients whose experiences give that work urgency.
Five developments stood out.
An ambitious international trial plan
The planned approximately 500-patient trial would take NeOnc’s research into a substantially larger clinical setting, extending evaluation beyond the smaller patient groups discussed in its early clinical experience.
With around 30 hospitals envisioned across three countries, the proposed study represents a significant development goal for the company. These figures describe planned participation, rather than completed enrollment.
Taking on the blood-brain barrier
The brain’s natural defenses can also stand in the way of treatment. The blood-brain barrier protects the brain, but it can prevent potential therapies from reaching tumors.
NeOnc’s investigational NEO100 program approaches that challenge through intranasal administration, a delivery method designed to carry therapy through the nose to the brain while bypassing the blood-brain barrier. The approach makes drug delivery itself a central part of the company’s treatment strategy.
Matching treatment to tumor biology
The discussion also highlighted NeOnc’s precision medicine approach: identifying molecular characteristics that may help determine which patients could respond to treatment.
Researchers discussed IDH mutations and the evaluation of NEO100 in patients with these tumor characteristics. By pairing targeted patient selection with intranasal delivery, NeOnc is investigating both how a therapy reaches the brain and whom it may help.
Early findings provide a reason to keep advancing
The discussion drew attention to earlier clinical observations, including a reported
Those findings give the larger research effort a meaningful foundation to investigate. They remain preliminary observations from a small, nonrandomized population and do not establish treatment effectiveness or predict individual outcomes.
More time with family is the goal
The patient stories brought the purpose of the research into focus. One patient described reaching two years on therapy and reported tolerating treatment without reactions and when Dr Drew asked her doctor if the tumor was staying or regressing, Dr. Wallace responded, “We can’t see it, actually, at this moment.”
Physicians spoke about what additional time could mean: another birthday, another anniversary and more moments with loved ones. These individual experiences cannot establish how other patients will respond, but they underscore why further research matters.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a2f0b9e4-f888-425c-9ee5-6a6c9975ec07
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How large is NeOnc's proposed international brain cancer trial?
NeOnc plans a trial targeting approximately 500 patients across around 30 hospitals in three countries. These figures represent planned participation, not completed enrollment.
What remission findings has NeOnc reported for NEO100?
NeOnc's December 2025 clinical update reported significant radiographic remission in six of 25 patients across combined clinical and compassionate-use experience. The observations are preliminary and drawn from a small, nonrandomized population; they do not establish treatment effectiveness or predict individual outcomes.